China agrees to pave the way for Indian Pharma to get market access: Suresh Prabhu

Inaugurating the 6th annual International Exhibition of Pharma and Healthcare (iPHEX), the Minister assured the global pharmaceutical players and regulators, of best quality and affordability of the Indian drugs.

China agrees to pave the way for Indian Pharma to get market access: Suresh Prabhu

New Delhi:  Commerce and Industry Minister Suresh Prabhu on Tuesday said that the government is committed to promoting pharmaceutical exports to untapped markets, including China which has agreed for a high level bilateral Round Table to pave the way for Indian Pharma to get market access and penetration in their vast market.

Inaugurating the 6th annual International Exhibition of Pharma and Healthcare (iPHEX), the Minister assured the global pharmaceutical players and regulators, of best quality and affordability of the Indian drugs.

He emphasised the need for reaching out to newer markets, especially in Africa, where affordability is the key issue, which can be very well addressed by the Indian exporters. He stressed on the need of both competitive and complementary strategies, so that each segment of Pharmaceutical sector can benefit. He further said that there is need to make both traditional and preventive medicine, to work together.  He also said that Genomics is the new branch in medicine, which can play a major role for the Indian Pharmaceutical sector.

Enumerating the measures to improve Ease of Doing Business, the Drugs Controller General of India, Eswara Reddy, announced increasing the validity of the GMP (Good Manufacturing Practices) Certificate, from two to three years. He further stated that protocol for clinical trials approval has also been changed, setting the time line of 45 days. Once approval does not come within this timeline, the protocol would have deemed to be approved.

Chairman of the Pharmaceuticals Export Promotion Council of India (PHARMEXCIL) Madan Mohan Reddy expressed confidence that the global business will be retained in India because of competitive cost of production. He complimented the Commerce and Industry Ministry for taking several measures to make India the main source of global manufacturing in pharmaceuticals.

 

By continuing to use the site, you agree to the use of cookies. You can find out more by clicking this link

Close